Viridian Therapeutics, Inc. (VRDN)
NASDAQ · Healthcare
$18.56+2.94%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.78B
- P/E ratio
- —
- EPS
- —
- Volume
- 2,153,039
- 52-week high
- —
- 52-week low
- —
- Open
- $18.17
- Day high
- $19.22
- Day low
- $18.15
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$342.6M | — |
| 2024 | — | -$269.95M | — |
| 2023 | — | -$237.73M | -$5.31 |
| 2022 | — | -$129.87M | -$4.05 |
| 2021 | — | -$79.41M | -$6.66 |
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
- CEO
- Stephen F. Mahoney
- Employees
- 252
- Country
- US
- IPO date
- Jun 18, 2014
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Viridian Therapeutics, Inc.'s stock price today?
- VRDN is trading at $18.56 as of Jul 20, 2026.
- What is Viridian Therapeutics, Inc.'s market cap?
- Viridian Therapeutics, Inc. (VRDN) has a market capitalization of $1.78B.
- Does Viridian Therapeutics, Inc. pay a dividend?
- Viridian Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Viridian Therapeutics, Inc. in?
- Viridian Therapeutics, Inc. operates in the Healthcare sector.